CN1993136A - 血清淀粉状蛋白a基因在诊断和治疗青光眼和鉴定抗青光眼活性剂中的用途 - Google Patents

血清淀粉状蛋白a基因在诊断和治疗青光眼和鉴定抗青光眼活性剂中的用途 Download PDF

Info

Publication number
CN1993136A
CN1993136A CNA200480037061XA CN200480037061A CN1993136A CN 1993136 A CN1993136 A CN 1993136A CN A200480037061X A CNA200480037061X A CN A200480037061XA CN 200480037061 A CN200480037061 A CN 200480037061A CN 1993136 A CN1993136 A CN 1993136A
Authority
CN
China
Prior art keywords
saa
seq
gene
glaucomatous
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480037061XA
Other languages
English (en)
Chinese (zh)
Inventor
A·F·克拉克
王万恒
L·麦克纳特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1993136A publication Critical patent/CN1993136A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA200480037061XA 2003-12-17 2004-12-01 血清淀粉状蛋白a基因在诊断和治疗青光眼和鉴定抗青光眼活性剂中的用途 Pending CN1993136A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53043003P 2003-12-17 2003-12-17
US60/530,430 2003-12-17

Publications (1)

Publication Number Publication Date
CN1993136A true CN1993136A (zh) 2007-07-04

Family

ID=34710163

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480037061XA Pending CN1993136A (zh) 2003-12-17 2004-12-01 血清淀粉状蛋白a基因在诊断和治疗青光眼和鉴定抗青光眼活性剂中的用途

Country Status (13)

Country Link
US (3) US7357931B2 (fr)
EP (1) EP1694192A4 (fr)
JP (2) JP4827742B2 (fr)
CN (1) CN1993136A (fr)
AR (2) AR048135A1 (fr)
AU (1) AU2004304944B2 (fr)
BR (1) BRPI0417732A (fr)
CA (1) CA2545777A1 (fr)
MX (1) MXPA06006503A (fr)
RU (1) RU2365379C2 (fr)
TW (1) TWI398261B (fr)
WO (1) WO2005060542A2 (fr)
ZA (1) ZA200603464B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103954765A (zh) * 2012-07-24 2014-07-30 国立中央大学 分析试剂盒及分析方法
CN108299551A (zh) * 2018-02-09 2018-07-20 北京市华信行生物科技有限公司 血清淀粉样蛋白a1突变体及其制备方法和应用
CN113186275A (zh) * 2021-06-16 2021-07-30 上海交通大学医学院附属仁济医院 血清淀粉样蛋白a1在制备作为诊断多囊卵巢综合征的生物标记物中的用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US20050137122A1 (en) * 2003-12-17 2005-06-23 Alcon, Inc. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US20060121039A1 (en) * 2004-12-07 2006-06-08 Alcon, Inc. Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
US20060154981A1 (en) * 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
RU2499599C2 (ru) 2007-09-28 2013-11-27 Интрексон Корпорейшн Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение
US20110067123A1 (en) * 2008-02-19 2011-03-17 Julie Andersen Mao-b elevation as an early parkinson's disease biomarker
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
DK2968139T3 (en) * 2013-03-14 2018-06-25 Eyecro Llc PLATFORM FOR TOPIC SUBMISSION OF MICROEMULSION
WO2017082393A1 (fr) * 2015-11-12 2017-05-18 学校法人 聖マリアンナ医科大学 Agent prophylactique et thérapeutique contre le glaucome
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
CN113244225B (zh) * 2021-06-16 2022-06-28 昆明医科大学第一附属医院 土槿皮乙酸在制备抗血小板药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) * 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) * 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
CA2153387A1 (fr) 1993-01-07 1994-07-21 Hubert Koester Sequencage de l'adn par spectrometrie de masse
US5593826A (en) * 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5606043A (en) * 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
US7718697B2 (en) * 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103954765A (zh) * 2012-07-24 2014-07-30 国立中央大学 分析试剂盒及分析方法
CN108299551A (zh) * 2018-02-09 2018-07-20 北京市华信行生物科技有限公司 血清淀粉样蛋白a1突变体及其制备方法和应用
CN113186275A (zh) * 2021-06-16 2021-07-30 上海交通大学医学院附属仁济医院 血清淀粉样蛋白a1在制备作为诊断多囊卵巢综合征的生物标记物中的用途

Also Published As

Publication number Publication date
TW200520768A (en) 2005-07-01
AR048135A1 (es) 2006-04-05
WO2005060542A2 (fr) 2005-07-07
TWI398261B (zh) 2013-06-11
AU2004304944B2 (en) 2010-06-10
AR077599A2 (es) 2011-09-07
RU2006125428A (ru) 2008-01-27
US20050153927A1 (en) 2005-07-14
US7357931B2 (en) 2008-04-15
MXPA06006503A (es) 2008-02-13
ZA200603464B (en) 2007-07-25
EP1694192A4 (fr) 2010-12-08
EP1694192A2 (fr) 2006-08-30
JP2011157398A (ja) 2011-08-18
WO2005060542A3 (fr) 2006-10-26
US20120064532A1 (en) 2012-03-15
RU2365379C2 (ru) 2009-08-27
JP2007514783A (ja) 2007-06-07
BRPI0417732A (pt) 2007-04-03
JP4827742B2 (ja) 2011-11-30
US20090036371A1 (en) 2009-02-05
AU2004304944A1 (en) 2005-07-07
CA2545777A1 (fr) 2005-07-07

Similar Documents

Publication Publication Date Title
CN1993136A (zh) 血清淀粉状蛋白a基因在诊断和治疗青光眼和鉴定抗青光眼活性剂中的用途
CN1466466A (zh) 心衰治疗剂
CN101563081A (zh) 血清淀粉样蛋白a基因在诊断和治疗青光眼以及在鉴定抗青光眼物质中的用途
CN1829804A (zh) 治疗认知功能障碍的靶位
CN1094446A (zh) Eck受体配体
CN1916167A (zh) 过氧化物酶体增殖物激活受体的调节
CN1849400A (zh) 红细胞生成素基因的新的多核苷酸和多肽
CN1609616A (zh) 糖尿病的特异性标记
CN1856709A (zh) 以斑点部位亢进基因群为指标而预知皮肤斑点形成的方法、筛选皮肤斑点形成抑制物的方法
CN1390255A (zh) 与疾病相关的基因用途
CN1619312A (zh) 代谢综合征的特异标记
CN1390256A (zh) 新型蛋白质及其dna
CN1771039A (zh) sgk基因家族用于诊断和治疗白内障和青光眼的用途
CN1633498A (zh) 新型胰岛素/胰岛素样生长因子/松弛素家族多肽及其dna
CN1708589A (zh) Cns中crh应答基因
CN1671734A (zh) 用于治疗囊性纤维化的cftr修饰基因和表达的多肽以及检测和/或鉴定它们的方法和产品
CN1211486C (zh) 编码前神经肽y原突变体,一种信号肽的突变体,的dna分子及其应用
CN1399644A (zh) 新的人g蛋白偶联受体
CN1875100A (zh) BACE455,人β－分泌酶的可变剪接变体
CN1222616C (zh) 具有抑癌功能的新的人蛋白及其编码序列
CN1177050C (zh) 编码具有抑制癌细胞生长功能的人蛋白的多核苷酸
CN1875275A (zh) 用于预测药物诱导的腹泻的生物标志
CN1229386C (zh) 具有抑癌功能的新的人蛋白及其编码序列
CN1155615C (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
CN1809588A (zh) 调节骨相关活性的新方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication